Crouzon Syndrome - 4 Studies Found

Terminated : Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)
: Medical Oncology
: 2015-02-16
: Drug: BAY1187982 A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the start
Active, not recruiting : Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
: Solid Tumor
: 2012-12-14
: Drug: ARQ 087 Subjects in this study will receive ARQ 087 orally at dose levels specified for their resp
Recruiting : Dovitinib for Gastric Cancer With FGFR2 Amplification
: Gastric Cancer
: 2012-10-22
: Drug: Dovitinib
  • Study trea
Not yet recruiting : Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer
:
  • FGFR Gene Amplification
  • FGFR1 Gene Amplification
  • : 2016-03-01
    :
    • Other: Laboratory Biomarker Analysis